Asahi SongwonQ4 FY23
Asahi Songwon Q4 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹364P/E: 12.3Market Cap: ₹429 CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- The Blue business is expected to remain a cash cow with no major capex; moderate growth around 10% is unlikely.
- Peak capacity turnover around INR 800 crores group-wide is possible, with expected revenue between INR 700-750 crores in 2-3 years after ramp-up.
- Chhatral facility external sales expected to reach INR 200 crores at peak.
- Dahej AZO dyes segment targeting to increase from INR ~45 crores to ~INR 90 crores in FY24, driven mainly by domestic sales and expanding yellow pigment capacity.
- Yellow pigments expected to dominate 70-75% of turnover for next 3 years, with capacity expansion underway.
- New small molecule API products (2-4) to be launched gradually; however, these won't significantly impact top-line immediately.
- Pregabalin remains key API product with plans for backward integration and approvals for export markets to improve margins and utilization over 3 years.
- Overall target is 15-17% EBITDA margins on normalized peak revenues.
See what Asahi Songwon management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- There was a suggestion for a smaller rights issue of INR 30-40 crores to improve liquidity; this has been considered internally by the team.
- No explicit confirmation of immediate fundraising via debt or equity was provided during the call.
- Management indicated no need to defer acquisitions or capital expenditures, implying sufficient current liquidity and no urgent requirement for fresh funding.
- Planned capex is limited to ongoing projects (Atlas Chhatral and ATC), totaling around INR 40 crores, after which the company intends to enter a consolidation phase lasting at least a year and a half with no new capex.
- Management expects to de-lever the balance sheet in a planned fashion post peak capex.
- No mention of new large-scale debt raising; existing debt peaks at INR 210 crores and is to be reduced afterward.
See what Asahi Songwon management said on order book — free account, 30 seconds.
Capex plans
Yes- Current capex includes INR 70 crores investment in the Chhatral plant aimed at backward integration for the API business, expected to achieve around INR 200 crores external sales at peak.
- Additional capex of about INR 30 crores is planned for doubling AZO dye capacities, particularly yellow, adding approx. 1,200 tons capacity with INR 10-14 crores capex; expansion expected to complete within 8-9 months.
- No new capital expenditure planned beyond the two ongoing projects (Atlas Chhatral and ATC) for at least one to two years; company will enter a consolidation phase post-completion.
- Plans to invest in renewable energy (wind and solar) are mentioned but no significant capex is planned currently for these.
- Management is considering a smaller rights issue (INR 30-40 crores) to boost liquidity.
- Focus over the next 3-5 years is on ramping up multiple products at various locations, aiming for INR 1,000 crores revenue goal.
Track Asahi Songwon — get its next earnings analysis in your feed
Margin guidance
Category 3- The worst quarters are behind, with Q1 FY24 (April-June) expected better than Q4 FY23; no similar downturn anticipated again.
- Business is bottoming out with global supply chain inventory at lows; demand revival expected leading to recovery of cash cow (Blue business).
- Peak capacity turnover estimated around INR 800 crores on group basis, with more realistic INR 700-750 crores achievable, maintaining 15-17% EBITDA margins long term.
- AZO segment expected to grow from ~INR 41 crores to INR 90 crores in FY24, driven by increased volumes and new shifts.
- Chhatral plant to contribute INR 200 crores top-line (external sales) at peak, supporting backward integration and margin improvement in API segment.
- API business (dominated by pregabalin) expected to consolidate and grow via approvals for regulated markets over 3-5 years, introducing higher value products.
- Overall, confidence expressed for revenue and profit improvement in coming quarters and years, aiming for INR 1,000 crores turnover in medium term.
Order book
- No explicit mention of current or expected orderbook or pending orders is provided on page 28 or related pages.
- However, references indicate ongoing customer approvals and business ramp-ups:
- - European and U.S. customers are in testing phases; it may take about six months for some to start orders (Page 27).
- - Revival and increased demand expected from European customers such as Sun, Siegwerk, and Clariant (Page 15-18).
- - Current business from European customers is minimal except for TTC, with around 90% sales in India for AZO dyes segment (Page 20).
- The company is confident of improved results in coming quarters and expects consolidation phase by second half of 2024 (Page 28).
- New product launches and expansions (Chhatral plant, Dahej yellow line expansion) will support future order growth (Pages 19-26).
How does Asahi Songwon rank vs peers in Chemicals & Petrochemicals?
Pro featureThisAsahi Songwon
Rev 3Mar 3
How does Asahi Songwon rank in Chemicals & Petrochemicals?
Compare Asahi Songwon against every Chemicals & Petrochemicals company (Q4 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Asahi Songwon's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Ch. (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF Ltd (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
- Deepak Fertilis. (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…